Curis Announces FDA Partial Clinical Hold For TakeAim Lymphoma Study Of Emavusertib
Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has placed a partial
